Systemic Lupus Erythematosus

Pregnant women with systemic lupus erythematosus often discontinue their lupus medications during pregnancy despite recommendations to continue them.

Plasma microbial translocation may play a role in the development of autoantibodies in systemic lupus erythematosus, researchers find. The discovery may lead to new treatments in lupus.

Over the past 20 years, while the demographics of systemic lupus erythematosus (SLE) hospitalizations have not noticeably changed, the comorbidities that lead to hospitalizations and poor outcomes in SLE have changed.

A 20-year analysis of hospitalizations due to compliations from systemic lupus erythematosus, shows new patterns in hospitalization rates, disease complications and mortality. In this slideshow, we highlight the findings.

Steriod-related damage builds over time for patients with childhood-onset lupus leading to cataracts, avascular necrosis, diabetes and osteoporotic fractures. Learn more in this slideshow.

New results for baricitinib and ustekinumab use in patients with systemic lupus erythematosus (SLE) were presented in April at the International Congress on Systemic Lupus Erythematosus (LUPUS 2019), which was held in San Francisco. Here, we summarize those results, plus much more from the meeting.

The prevalence of systemic lupus erythematosus (SLE) is higher among black patients. They can present with a worsened disease state and mortality rates can be higher. This suggests a need for better therapeutic options, says Jim C. Oates, M.D., of Medical University of South Carolina. In this Q&A, Dr. Oates addresses treatment challenges black patients face.

Fatigue in patients with systemic lupus erythematosus (SLE) has been linked to anti-NR2 antibodies, which responds to treatment with belimumab, a study shows.

We have come a long way since the introduction of glucocorticoids for the treatment of systemic lupus erythematosus (SLE). But even with improved treatment and prognosis several challenges remain in the management of SLE. Here, we highlight the 10 most important challenges in treating patients with SLE.

While rituximab has proven to be an effective treatment for rheumatoid arthritis, it has failed to meet its primary endpoints in clinical trials for systemic lupus erythematosus (SLE). But now, an observational study suggests that rituximab could be effective as maintenance therapy in difficult SLE cases.

A study published last month in Arthritis Care & Research shows that racial/ethnic minorities disproportionately have more severe cases of systemic lupus erythematosus (SLE). In this slideshow, we summarize the findings, but we'd like to know what you think. Email us your comments at areyes@mmhgroup.com.

In this slideshow, we highlight the news you may have missed:  Prescribing information for a newly approved treatment for pediatric lupus, new reports on negative pregnancy outcomes in PsA and ankylosing spondylitis, new information on the benefits of daily tofacitinib, and much more.

African American women are disproportionately likely to develop systemic lupus erythematosus, and their disease course is more severe than other demographic groups, says Dr. Edith Williams. In this Q&A, she introduces us to a peer-mentoring program designed to foster self-management.

The expanded indication allows the use of intravenous belimumab (Benlysta) in children as young as 5 years of age.

Patients with systemic lupus erythematosus often have a range of clinical symptoms that are nonspecific and overlap with other medical conditions, such as Sjögren’s syndrome, rheumatoid arthritis and Raynaud's syndrome.

Drug-induced lupus and systemic lupus erythematosus (SLE) are two entirely different entities. Failure to identify SLE could lead to worsening symptoms, researchers say.

A new study published online ahead of print in Arthritis Care & Research sheds light on the barriers rheumatology patients face with regards to smoking cessation while describing individual reactions to cessation protocols and identifying patient centered outcomes after improvements in care.

Using a frailty index to predict adverse outcomes and mortality in systemic lupus erythematosus proves to be feasible and effective in a study. The test, SLICC-FI, correlated well with existing measures of SLE disease activity, organ damage and HRQoL.

A recent study published in Arthritis & Rheumatology has demonstrated that belimumab is both safe and effective in patients with systemic lupus erythematosus and provides disease control over the long term.

Higher lupus disease activity may be associated with bacteria from periodontal disease, which may be an important modifiable mediator of SLE disease activity.

In this quiz, we revisit recent advances made in systemic lupus erythematosus (SLE).

Increased cancer risk, a new measure for disease outcomes and a new treatment are among the developments in systemic lupus erythematosus (SLE) published in recent months. Learn more in this slideshow.

This meta-analysis confirms and clarifies the link between SLE and certain types of cancer.

Test your knowledge of the featured topics and findings reported at rheumatology’s annual educational gathering.

How to ensure your patients with lupus receive the vaccines they need.